Cargando…

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision

BACKGROUND: Hydroxyurea (HU) is underutilized in children with sickle cell disease (SCD) because caregivers frequently decline HU when it is offered. This study explores what impacts this decision. RESULTS: Caregivers of children with clinically severe SCD whose children were offered HU previously w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creary, Susan, Zickmund, Susan, Ross, Diana, Krishnamurti, Lakshmanan, Bogen, Debra L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548690/ https://www.ncbi.nlm.nih.gov/pubmed/26303306 http://dx.doi.org/10.1186/s13104-015-1344-0

Ejemplares similares

Primary caregiver decision-making in hematopoietic cell transplantation and gene therapy for sickle cell disease
por: Sinha, Cynthia B., et al.
Publicado: (2020)

From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
por: Sinha, Cynthia B., et al.
Publicado: (2018)

Assessment of Patient and Caregiver Attitudes and Approaches to Decision-Making Regarding Bone Marrow Transplant for Sickle Cell Disease: A Qualitative Study
por: Bakshi, Nitya, et al.
Publicado: (2020)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial
por: Hood, Anna M, et al.
Publicado: (2021)

A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring
por: Creary, Susan E., et al.
Publicado: (2017)

A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study
por: Creary, Susan, et al.
Publicado: (2019)

A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study
por: Veludhandi, Anirudh, et al.
Publicado: (2021)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Decision-making about gene therapy in transfusion dependent thalassemia
por: Quarmyne, Maa-Ohui, et al.
Publicado: (2022)

Presence of pain on three or more days of the week is associated with worse patient reported outcomes in adults with sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2018)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Hematopoietic Cell Transplantation for Sickle Cell Disease
por: Krishnamurti, Lakshmanan
Publicado: (2021)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Acute Chest Syndrome in Children with Sickle Cell Disease
por: Jain, Shilpa, et al.
Publicado: (2017)

Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study
por: Sinha, Cynthia B., et al.
Publicado: (2019)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
por: Bakshi, Nitya, et al.
Publicado: (2017)

Sickle cell trait knowledge and health literacy in caregivers who receive in‐person sickle cell trait education
por: Creary, Susan, et al.
Publicado: (2017)

Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost
por: Costa, Enrico, et al.
Publicado: (2020)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemia
por: Meier, Emily R., et al.
Publicado: (2020)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
por: Katoch, Deeksha, et al.
Publicado: (2021)

How Hydroxyurea Alters the Gut Microbiome: A Longitudinal Study Involving Angolan Children with Sickle Cell Anemia
por: Delgadinho, Mariana, et al.
Publicado: (2022)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
por: McGann, Patrick T., et al.
Publicado: (2015)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

Patient and family experience with chronic transfusion therapy for sickle cell disease: A qualitative study
por: Hawkins, Lauren M., et al.
Publicado: (2020)

Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
por: Chiang, Kate Chander, et al.
Publicado: (2023)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1iophrv3eeauuqgile6agg3uup